Globus Medical
GMED
73.75
-2.68
-3.51%
Globus Medical
US · GMED
#1454 by market cap
Listed 1970
73.75
-2.68
-3.51%
Live - 5344 symbols - heartbeat 565s ago
· 2026-10-08 07:16
Pre-market
73.50
-0.34%
After-hours
76.00
+3.05%
- Market cap
- 9.90B
- P/E (TTM)i
- 18.86
- P/Bi
- 2.08
- EPSi
- 3.92
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on GMED?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.77, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.65% YoY
Margins
- Gross margin
- 67.41%
- Operating margin
- 18.28%
- Net margin
- 18.30%
Key ratios & quality
- PEG ratioi
- 0.46
- Altman Z-Scorei
- 9.77
PEG uses trailing P/E against the 3-year net income growth rate (41.42%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 712.97M | 785.37M | 789.04M | 958.10M | 1.02B | 1.57B | 2.52B | 2.94B |
| Gross profit | 553.56M | 605.39M | 571.58M | 718.88M | 759.12M | 1.02B | 1.48B | 1.98B |
| Selling & admin expenses | 311.59M | 354.76M | 354.76M | 408.15M | 432.12M | 643.84M | 981.36M | 1.18B |
| Research & development | 55.50M | 60.07M | 84.52M | 97.35M | 73.02M | 124.01M | 163.75M | 147.25M |
| Operating profit | 176.88M | 176.75M | 115.47M | 194.86M | 236.25M | 201.42M | 219.39M | 537.19M |
| Pretax profit | 188.61M | 189.95M | 125.90M | 180.41M | 243.02M | 165.39M | 120.72M | 605.07M |
| Tax | 32.13M | 34.74M | 23.61M | 31.22M | 52.85M | 42.52M | 17.74M | 67.20M |
| Net profit | 156.47M | 155.21M | 102.29M | 149.19M | 190.17M | 122.87M | 102.98M | 537.87M |
| Basic EPS | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 4 |
| Diluted EPS | 1.54 | 1.52 | 1.01 | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 598.12M | 745.34M | 769.05M | 826.42M | 759.85M | 789.61M |
| Gross profit | 402.72M | 496.58M | 516.52M | 565.31M | 525.79M | 548.17M |
| Selling & admin expenses | 242.80M | 303.62M | 313.60M | 318.48M | 297.78M | 286.82M |
| Research & development | 33.06M | 39.95M | 38.07M | 36.16M | 36.51M | 36.32M |
| Operating profit | 98.06M | 122.81M | 135.01M | 181.31M | 161.98M | 195.47M |
| Pretax profit | 103.67M | 188.17M | 143.99M | 169.23M | 157.07M | 189.82M |
| Tax | 28.21M | -14.67M | 25.03M | 28.64M | 32.77M | 38.25M |
| Net profit | 75.46M | 202.85M | 118.97M | 140.59M | 124.30M | 151.57M |
| Basic EPS | 1 | 2 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.54 | 1.49 | 0.88 | 1.03 | 0.90 | 1.10 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 630.68M | 687.47M | 821.77M | 864.52M | 983.34M | 1.92B | 2.18B | 2.13B |
| Cash & ST investments | 339.58M | 311.49M | 426.74M | 443.45M | 446.06M | 517.79M | 890.06M | 557.24M |
| Inventory | 131.25M | 196.31M | 229.15M | 237.00M | 298.98M | 848.14M | 659.23M | 759.28M |
| Total assets | 1.30B | 1.53B | 1.68B | 1.96B | 2.08B | 5.09B | 5.25B | 5.30B |
| Total current liabilities | 96.12M | 111.40M | 120.79M | 140.16M | 159.20M | 392.35M | 855.91M | 498.50M |
| Short-term debt | -- | -- | -- | -- | 2.54M | 11.97M | 453.60M | 14.74M |
| Long-term debt | -- | -- | -- | -- | -- | 417.40M | -- | -- |
| Total liabilities | 115,154,000.00 | 129,625,000.00 | 173,188,000.00 | 215,875,000.00 | 229,753,000.00 | 1,088,124,000.00 | 1,074,417,000.00 | 729,511,000.00 |
| Total equity | 1.19B | 1.40B | 1.51B | 1.74B | 1.85B | 4.00B | 4.18B | 4.57B |
| Retained earnings | 892.72M | 1.05B | 1.05B | 1.19B | 1.24B | 1.14B | 1.15B | 1.39B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.71B | 1.73B | 1.92B | 2.13B | 2.20B | 2.22B |
| Cash & ST investments | 461.27M | 229.45M | 390.52M | 557.24M | 629.85M | 595.14M |
| Inventory | 663.60M | 772.13M | 771.54M | 759.28M | 772.60M | 810.90M |
| Total assets | 4.71B | 4.96B | 5.10B | 5.30B | 5.44B | 5.49B |
| Total current liabilities | 384.70M | 424.66M | 465.96M | 498.50M | 482.46M | 479.35M |
| Short-term debt | 10.62M | 13.18M | 14.36M | 14.74M | 15.12M | 14.39M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 623,080,000.00 | 665,406,000.00 | 696,815,000.00 | 729,511,000.00 | 707,243,000.00 | 719,655,000.00 |
| Total equity | 4.09B | 4.30B | 4.40B | 4.57B | 4.73B | 4.77B |
| Retained earnings | 1.04B | 1.21B | 1.29B | 1.39B | 1.51B | 1.53B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 181.64M | 171.98M | 198.79M | 276.27M | 178.47M | 243.50M | 520.64M | 753.45M |
| Depreciation & amortization | 41.63M | 52.73M | 62.87M | 69.87M | 68.25M | 145.53M | 253.39M | 276.84M |
| Free cash flow | 121.95M | 101.23M | 135.14M | 219.38M | 104.42M | 165.23M | 405.21M | 579.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 39.31M | 31.04M | -104.67M | 0 | -144.49M | -225.56M | -85.79M | -300.45M |
| Ending cash balance | 139.75M | 195.72M | 239.40M | 193.07M | 150.47M | 467.29M | 784.44M | 526.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 177.30M | 77.87M | 249.70M | 248.59M | 202.36M | 209.74M |
| Depreciation & amortization | 65.65M | 70.63M | 71.55M | 69.01M | 69.86M | 69.50M |
| Free cash flow | 141.20M | 31.30M | 204.21M | 202.31M | 162.75M | 176.57M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -190.45M | -25.00M | -40.00M | -45.00M | 0 | -136.06M |
| Ending cash balance | 461.27M | 229.45M | 371.77M | 526.16M | 560.95M | 507.75M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 14.53 | 11.99 | 7.03 | 9.19 | 10.60 | 4.20 | 2.52 | 12.29 |
| ROA %i | 13.15 | 10.96 | 6.37 | 8.20 | 9.43 | 3.43 | 1.99 | 10.19 |
| ROIC %i | 13.51 | 10.90 | 7.03 | 9.19 | 10.60 | 3.57 | 2.23 | 11.44 |
| 5-year avg ROE %i | 14.96 | 13.86 | 11.80 | 10.94 | 10.67 | 8.60 | 6.71 | 7.76 |
| EBIT margin %i | 24.59 | 21.97 | 14.63 | 20.34 | 23.10 | 12.87 | 8.72 | 18.28 |
| FCF / sales %i | 17.10 | 12.89 | 17.13 | 22.90 | 10.21 | 10.53 | 16.08 | 19.70 |
| Current ratioi | 6.56 | 6.17 | 6.80 | 6.17 | 6.18 | 4.88 | 2.54 | 4.26 |
| Quick ratioi | 5.03 | 4.25 | 4.76 | 4.35 | 4.17 | 2.61 | 1.72 | 2.61 |
| Debt / assetsi | -- | -- | -- | -- | 0.29 | 10.23 | 10.23 | 2.24 |
| LT debt / equityi | -- | -- | -- | -- | 0.19 | 12.72 | 2.00 | 2.27 |
| Interest coveragei | -13.20 | -9.91 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 9.38 | 11.67 | 7.45 | 10.35 | 9.21 | 25.74 | 38.03 | 42.17 |
| Net income CAGR (3Y) %i | 11.53 | 14.15 | -1.60 | -1.58 | 7.01 | 6.30 | -11.62 | 41.42 |
| FCF CAGR (3Y) %i | 18.52 | -1.81 | 7.84 | 21.62 | 1.04 | 6.93 | 22.70 | 77.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 4.63 | 8.62 | 10.01 | 12.29 | 13.30 | 11.81 |
| ROA %i | 3.84 | 7.17 | 8.32 | 10.19 | 11.56 | 10.25 |
| ROIC %i | 4.30 | 7.99 | 9.29 | 11.44 | 13.00 | 11.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 11.48 | 13.26 | 15.65 | 18.28 | 19.39 | 21.42 |
| FCF / sales %i | 20.61 | 19.89 | 20.58 | 19.70 | 19.37 | 23.72 |
| Current ratioi | 4.45 | 4.07 | 4.13 | 4.26 | 4.56 | 4.62 |
| Quick ratioi | 2.60 | 2.09 | 2.31 | 2.61 | 2.83 | 2.78 |
| Debt / assetsi | 1.96 | 2.44 | 2.34 | 2.24 | 2.12 | 2.03 |
| LT debt / equityi | 2.00 | 2.51 | 2.39 | 2.27 | 2.12 | 2.03 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Musculoskeletal Solutions is the largest reported line at 96.70% of revenue, across 2 reported segments.
- The next-largest line, Enabling Technologies, is a distant second at 3.30% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Musculoskeletal Solutions96.70%
Enabling Technologies3.30%
Quote time 2026-10-08 07:16:36 · For reference only, not investment advice and not tailored to your situation.